References
Greer M, Monteban H. A review of quality of life in Alzheimer’s disease. Parts 1 and 2: issues in assessing disease impact and drug effects [letter]. Pharmacoeconomics 1999; 15 (6): 641
Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 1: issues in assessing disease impact. Pharmacoeconomics 1998; 14 (5): 499–530
Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 2: issues in assessing drug effects. Pharmacoeconomics 1998; 14 (6): 613–27
Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Parts 1 and 2: issues in assessing disease impact and drug effects [letter]. Pharmacoeconomics 1999; 15: 641–4
Whiteneck GG. Measuring what matters: key rehabilitation outcomes. Arch Phys Med Rehabil 1994; 75: 1073–6
Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA 1994; 272: 619–25
Heinemann AW, Whiteneck GG. Relationships among impairment, disability, handicap and life satisfaction in persons with traumatic brain injury. J Head Trauma Rehabil 1995; 10: 54–63
Doward LC, McKenna SP. Evolution of quality of life assessment. In: Rajagopalan R, Sheretz EF, Anderson RT, editoris. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker, 1997: 9–33
Doward LC. The development of the Alzheimer’s Carers’ Quality of Life Instrument (ACQLI) [abstract no. 88]. Qual Life Res 1997; 6 Suppl. 7–8: 639
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McKenna, S.P., Doward, L.C. A Review of Quality of Life in Alzheimer’s Disease. Pharmacoeconomics 16, 417 (1999). https://doi.org/10.2165/00019053-199916040-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199916040-00009